TIBET PHARMA(SH:600211) Zheng Xing Xing Ye Ri Bao·2025-09-08 08:53Core Insights - The biopharmaceutical sector experienced a 0.64% increase on September 8, with Tibet Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3826.84, up 0.38%, while the Shenzhen Component Index closed at 12666.84, up 0.61% [1] Biopharmaceutical Sector Performance - Tibet Pharmaceutical (600211) saw a closing price of 55.53, with a significant increase of 10.00% and a trading volume of 257,300 shares, amounting to a transaction value of 1.364 billion [1] - Kanghua Biological (300841) closed at 76.38, up 5.35%, with a trading volume of 63,500 shares and a transaction value of 484 million [1] - Sairun Biological (688163) closed at 25.35, up 4.71%, with a trading volume of 19,500 shares and a transaction value of 48.51 million [1] - Other notable performers include Jin Ke (688670) with a 3.35% increase, Mu Li Pharmaceutical (603087) and Wantai Biological (603392) both up 3.18% [1] Decliners in the Biopharmaceutical Sector - Sanofi Guojian (688336) experienced a decline of 6.07%, closing at 57.86, with a trading volume of 116,500 shares and a transaction value of 680 million [2] - Baiao Tai (688177) closed at 32.47, down 2.29%, with a trading volume of 37,900 shares and a transaction value of 124 million [2] - Other companies such as Yuansijinhai (836547) and Nuo Silan De (430047) also saw declines of 2.17% and 1.52% respectively [2] Capital Flow Analysis - The biopharmaceutical sector saw a net inflow of 76.9582 million from institutional investors, while retail investors experienced a net outflow of 56.6098 million [2][3] - Tibet Pharmaceutical had a net inflow of 246 million from institutional investors, while retail investors had a net outflow of 142 million [3] - Kanghua Biological had a net inflow of 49.0462 million from institutional investors, with retail investors experiencing a net outflow of 35.3677 million [3]